Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.
The FDA on Thursday approved an injectable drug that eased Parkinson's disease symptoms and improved motor fluctuations in ...
Parkinson's disease has been getting increased attention in the media, but misinformation abounds. Here, a Parkinson's expert ...
Parkinson's disease: early signs and symptoms to look out for after John Stapleton reveals diagnosis
BBC presenter John Stapleton has revealed he has been diagnosed with Parkinson’s disease. The 78-year-old who is best known ...
Tuesday, Sept. 24, former Green Bay Packer and NFL Hall of Fame quarterback Brett Favre testified before Congress. Favre was ...
The chemical messenger dopamine is an essential catalyst that fuels activities and behaviors ranging from movement to ...
Recent research suggests a gut-brain connection in Parkinson’s Disease, impacting diagnosis, progression, and treatment ...
In the supplementary post-hoc analysis, treatment with solengepras 150 mg group reduced OFF time by -1.78 hours (p= 0.0045) ...
Parkinson’s Disease Therapeutic MarketThe Global Parkinson’s Disease Industry is poised to achieve an estimated worth of USD 5.41 Billion, reflecting a notable increase from the USD 4.82 Billion ...
Caffeine Affects Brain Dopamine Function in Patients With Parkinson's Disease May 28, 2024 — Regular high caffeine consumption affects dopamine function in patients with Parkinson's disease ...
The FDA has just approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback